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Heart failure, which is among the most common and
disabling forms of cardiovascular disease, is closely associ-
ated with obesity (1). This is not a new observation, and as
highlighted in a historical treatise on the heart and obesity
by Alexander (2), in the 1700s the relationship of excess fat
deposition involving the heart in obese individuals was
reported. In the early 1800s, the fatty heart as an entity
was described, and in 1847, William Harvey reported in a
postmortem examination of a morbidly obese man that the
heart was “large, thick and ﬁbrous, with a considerable
quantity of adhering fat” (2). Although the association
between obesity and heart disease is well accepted, under-
lying pathophysiological processes remain elusive, and it is
unclear whether obesity cardiomyopathy is due to increased
adiposity itself or due to the effects of obesity-associated
comorbidities, including hypertension, metabolic syndrome,
and diabetes.
In obesity, the heart undergoes structural remodeling
due to interstitial ﬁbrosis, cardiomyocyte hypertrophy,
and cardiac steatosis, leading to functional alterations (3).
Molecular mechanisms associated with these processes in-
clude oxidative stress, natriuretic peptides, endothelin-1,
advanced glycation end products, and activation of the
renin-angiotensin-aldosterone system (RAAS) (4,5). In ad-
dition, inﬂammation is now considered to be important in
obesity-related heart disease, especially in the context of
diabetes and insulin resistance (6). In support of this are
studies demonstrating that adipocyte-derived factors (adi-
pokines) directly inﬂuence proinﬂammatory signaling in
the heart (7).
Common in many of the above processes is activation
of the RAAS, which is upregulated in obesity (5). Angio-
tensin (Ang) II, through the angiotensin type 1 receptor
(AT1R), promotes cardiovascular ﬁbrosis, inﬂammation,
and insulin resistance and plays a role in the cardiovas-
cular complications of diabetes and obesity. Recent evi-
dence indicates that cardiac steatosis ampliﬁes the injurious
actions of Ang II through reactive oxygen species (8),
thereby creating a feed-forward system where Ang II
promotes obesity cardiomyopathy, which enhances Ang II
actions. Although Ang II/AT1R promotes cardiovascular
injury and inﬂammation, there is growing evidence that
these actions are counterregulated by the protective arm
of the RAAS, comprising angiotensin-converting enzyme 2
(ACE2), Ang 1-7 (produced from Ang II by ACE2), and the
Mas receptor through which Ang 1-7 signals (9). Members
of the dual RAAS (ACE/Ang II/AT1R and ACE2/Ang 1-7/
Mas) have been identiﬁed in many cell types, including
adipocytes (10). This is of particular relevance in obesity
where adipocytes possess a local RAAS that contributes
to adipose inﬂammation, characteristically observed in ex-
perimental and human obesity (11). This has pathophysi-
ological signiﬁcance in the cardiovascular system because
perivascular adipose tissue is an important player in vas-
cular dysfunction in obesity-associated cardiovascular dis-
ease (12). Whether a similar relationship exists between
epicardial adipose tissue and cardiac function is unclear
and until now has not been comprehensively examined.
In this issue of Diabetes, Patel et al. (13) provide novel
data demonstrating that epicardial adipose tissue in obese
mice has a proinﬂammatory phenotype with associated
cardiac dysfunction, features that are exaggerated in
mice lacking ACE2. Associated with the marked inﬂam-
matory response in fat-fed ACE2-deﬁcient mice was de-
creased myocardial adiponectin (protective adipokine),
reduced AMPK signaling, myocardial insulin resistance,
and increased cardiac steatosis and lipotoxicity with wors-
ening of cardiac function; effects that were normalized by
Ang 1-7 administration. This study identiﬁes the ACE2/Ang
1-7/Mas system as a negative modulator of obesity cardio-
myopathy. Although the cardioprotective actions of ACE2/
Ang 1-7 are well known, the current study highlights its role
in epicardial adipose tissue. In fact, the importance of “fatty
epicardium” in obesity was described over 80 years ago when
postmortem cardiac ﬁndings in obese individuals showed
excess epicardial fat (14). What we now learn from Patel
et al. (13) is that this fat depot is biologically active and
that in obesity it is inﬂamed and inﬂuences myocardial
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signaling and metabolism as well as cardiac function through
processes that are ameliorated by ACE2/Ang 1-7/Mas (Fig. 1).
Although Patel et al. (13) have discovered an important
role for epicardial adipose tissue and ACE2/Ang 1-7 de-
ﬁciency in obesity-related cardiomyopathy, there are some
aspects that warrant further consideration. First, although
it is clearly shown that in the absence of ACE2, epicardial
adipose tissue differentiates into a proinﬂammatory phe-
notype, the authors do not reveal whether other adipose
depots and organs also become inﬂamed in the model
studied. This is important because it may be possible that
ubiquitous ACE2 knockout leads to a generalized inﬂam-
matory response, including in the myocardium, which could
directly impact on cardiac dysfunction independently of
epicardial inﬂammation. However, cross talk between inﬂamed
epicardial adipocytes and cardiomyocytes/ﬁbroblasts may
amplify underlying cardiac injury in ACE2 knockout mice.
Such cross talk is evidenced by the ﬁndings that epicardial
inﬂammation is linked to aberrant myocardial AMPK sig-
naling and insulin resistance (13). To fully appreciate the
exact role of epicardial adipose tissue in obesity cardiomy-
opathy, experiments in mice where ACE2 is knocked down
in an epicardial-speciﬁc manner are necessary.
Second, there appears to be some discordance between
epicardial ACE2 and cardiac function in obesity, because in
fat-fed obese wild-type mice with epicardial inﬂammation
and cardiac dysfunction, ACE2 expression was increased, yet
in mice with ACE2 deletion, epicardial adipose tissue also
had an inﬂammatory phenotype and exaggerated cardiac
changes (13). How can obesity cardiomyopathy and epicar-
dial inﬂammation be associated with both increased and
reduced ACE2 activity? While this enigma is not discussed
by the authors, it could be speculated that in obesity upreg-
ulation of ACE2 and its partners may compensate for in-
creased activation of the injurious arm of the RAAS and that
at a critical time point when the protective axis is over-
whelmed the ACE2/Ang 1-7/Mas system is decompensated
with consequent cardiac failure. This notion is supported by
other studies in mice fed high-fat diets, where with increas-
ing obesity, adipose ACE2 activity was blunted with a shift
in the RAAS to favor high Ang II levels (15).
Third, the study by Patel et al. (13) was performed in
male mice. Considering the fact that clinically heart fail-
ure with a preserved ejection fraction occurs more often
in obese females (16), one wonders whether epicardial
adipose inﬂammation and associated cardiac changes in
ACE2-deﬁcient fat-fed male mice would be exaggerated in
females. This may be especially relevant with respect to
ACE2/Ang 1-7/Mas because estrogens inﬂuence the RAAS.
In particular, Ang II/Ang 1-7 balance is differentially regu-
lated in obese male and female mice and contributes to
diverging susceptibilities to obesity-related cardiovascular
Figure 1—Diagram demonstrating possible mechanisms whereby ACE2 negatively regulates epicardial adipose tissue and cardiac func-
tion. In obesity, diabetes, metabolic syndrome, or conditions where there is activation of the RAAS, the cardioprotective arm of the RAAS
may be decompensated, leading to a proinﬂammatory phenotype of the epicardial adipose tissue. Cross talk between the epicardium and
myocardium leads to reduced myocardial AMPK and Akt signaling, insulin resistance, steatosis, and lipotoxicity, processes that underlie
cardiac dysfunction, which ultimately leads to heart failure. Administration of Ang 1-7 prevents these changes and protects against cardiac
injury and heart failure.
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disease (17). Further studies exploring the relationship be-
tween epicardial adipose tissue, the RAAS, and cardiomy-
opathy in female models of obesity may shed light on why
heart failure with a preserved ejection fraction is more
common in obese women.
Finally, an intriguing ﬁnding is the observation that
epicardial inﬂammation, cardiac metabolism, and heart
dysfunction were worse in high-fat diet–fed ACE2 knock-
out mice than in fat-fed controls, despite ACE2-deﬁcient
mice being less obese than their wild-type counterparts,
indicating an inverse association between adiposity car-
diomyopathy and body weight (13). The data suggest that
while obesity leads to cardiac dysfunction, as long as
ACE2 is present, there is some cardioprotection, a phe-
nomenon that is lost when ACE2 is absent. These obser-
vations may have important clinical relevance and may
explain, at least in part, the “obesity paradox,” where
overweight/obese patients with cardiovascular disease
have a more favorable outcome with less cardiovascular
events than lean individuals (18). Perhaps upregulation of
the ACE2/Ang 1-7/Mas system in obese subjects may be
related to “healthy” cardioprotective epicardial adipose
tissue, whereas in leaner individuals, this is blunted, lead-
ing to worse cardiac outcomes. Further investigation of
this paradigm may unravel some putative mechanisms
underlying the obesity paradox.
In summary, the ﬁndings by Patel et al. (13) raise some
thought-provoking ideas, such as the possible role of ACE2
in the obesity paradox and the potential for differential
ACE2/Ang 1-7 regulation in sex-linked obesity cardiomy-
opathy, and provide new insights into cardioprotective
mechanisms of ACE2/Ang 1-7/Mas in obesity. Speciﬁcally,
the study advances the ﬁeld by identifying epicardial
adipose tissue as an important target for ACE2 and its
partners, which when deﬁcient lead to an inﬂammatory re-
sponse that promotes impaired myocardial metabolism and
cardiac dysfunction. Considering the growing clinical inter-
est in orally active Ang 1-7 as a potential therapeutic agent
in many diseases (19,20), perhaps obesity-related cardiac
heart disease should be added to the list of conditions
that may beneﬁt from such an approach.
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